Rockwell Medical (RMTI) EBIT (2010 - 2026)

Rockwell Medical (RMTI) has reported EBIT for 17 consecutive years, with -$1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 21.35% year-over-year to -$1.1 million; the trailing twelve-month figure through Jun 2026 stood at -$4.5 million (down 250.08% YoY), and the FY2025 full-year result was -$4.7 million, down 871.55% from the prior year.
• EBIT advanced to -$1.1 million in Q2 2026 per RMTI's latest filing, from -$1.5 million in the prior quarter.
• Across five years, EBIT topped out at $1.9 million in Q3 2024 and bottomed at -$6.6 million in Q1 2022.
• Historically, EBIT has averaged -$1.7 million across 5 years, with a median of -$1.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: EBIT surged 211.46% in 2024, then plunged 361.94% in 2025.
• Over 5 years, EBIT stood at -$2.0 million in 2022, then surged by 72.18% to -$547000.0 in 2023, then rose by 5.12% to -$519000.0 in 2024, then climbed by 23.31% to -$398000.0 in 2025, then sank by 166.58% to -$1.1 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$1.1 million, -$1.5 million, and -$398000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.